Loading…
for educational and safety purposes
Memantine and Nitromemantine both come up in the same conversations. Memantine: Memantine (brand names Namenda and Ebixa) is an NMDA receptor antagonist approved for moderate to severe Alzheimer's disease; it calms excess glutamate signaling to protect neurons while leaving the normal signaling needed for memory and learning intact [1][2]. Nitromemantine: Nitromemantine is an experimental, two-in-one derivative of memantine developed largely by Stuart Lipton's group.
Memantine (brand names Namenda and Ebixa) is an NMDA receptor antagonist approved for moderate to severe Alzheimer's disease; it calms excess glutamate signaling to protect neurons while leaving the normal signaling needed for memory and learning intact [1][2]. What makes it unusual is its voltage-dependent, fast-off-rate binding; it blocks the constant, low-level 'noise' of glutamate but steps aside when a real learning signal arrives, so it doesn't cloud cognition the way stronger blockers (like ketamine) do. It is also more than a pure NMDA blocker; at or near therapeutic brain concentrations it reaches a spread of remote targets, agonizing the high-affinity state of the dopamine D2 receptor, antagonizing 5-HT3 serotonin receptors and several nicotinic acetylcholine receptors (alpha-7, alpha-4/beta-2, alpha-3/beta-4 and alpha-9/alpha-10), and weakly engaging sigma-1 receptors; see the affinity table below for the full fingerprint. Beyond Alzheimer's it is being investigated for a range of conditions; it shows the most promise for the negative symptoms of schizophrenia (social withdrawal, apathy, blunted motivation) and as a mood stabilizer in bipolar disorder, with earlier signals in ADHD (often as an adjunct to a stimulant), anxiety and OCD, and autism.
Nitromemantine is an experimental, two-in-one derivative of memantine developed largely by Stuart Lipton's group. It keeps memantine's aminoadamantane body, which parks inside overactive NMDA receptor channels (a major glutamate receptor), and bolts on a nitro/nitrate group that acts as a targeted warhead to deliver nitric oxide to a regulatory (redox) site on the same receptor. The idea is to shut down damaging, chronically overactive extrasynaptic NMDA receptors while sparing the normal synaptic signaling the brain needs to learn. It remains a preclinical research compound, studied in cell and animal models of Alzheimer's, autism-linked syndromes, tuberous sclerosis, Parkinson's-type synuclein damage, and depression; it is not an approved drug.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
non-competitive antagonist
agonist
uncompetitive, voltage-dependent open-channel antagonist
non-competitive open-channel antagonist
antagonist
negligible inhibitor
antagonist
antagonist
substrate and weak inhibitor
agonist
uncompetitive, fast off-rate channel block
rebalances hyperexcitable circuits
targeted nitric oxide donor / allosteric down-modulation
restores in stressed/diseased tissue
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.
easiest to source: Memantine is currently listed by more trusted vendors (2), so it's the simpler one to get hold of. for effects and safety, read each full entry; this is educational, not medical advice.